Literature DB >> 7915773

Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura.

V Blanchette1, P Imbach, M Andrew, M Adams, J McMillan, E Wang, R Milner, K Ali, D Barnard, M Bernstein.   

Abstract

The most serious complication of childhood acute immune thrombocytopenic purpura (ITP), intracranial haemorrhage, occurs in about 1% of children with platelet counts below 20 x 10(9)/L. We conducted a randomised study to explore three treatment options in this high-risk group. 146 children (> 6 months and < 18 years old) with typical acute ITP and platelet counts of 20 x 10(9)/L or lower were randomised to receive high-dose intravenous immunoglobulin G (IVIgG) 1 g/kg on 2 consecutive days (n = 34), 0.8 g/kg once (n = 35), intravenous anti-D 25 micrograms/kg on 2 consecutive days (n = 38), or oral prednisone 4 mg/kg per day with tapering and discontinuation of prednisone by day 21 (n = 39). The rate of response as reflected by the number of days with platelet counts at 20 x 10(9)/L or lower and the time taken to achieve a platelet count 50 x 10(9)/L or more was significantly faster for both IVIgG groups than for the anti-D group (p < 0.05); the difference between prednisone and IVIgG was significant (p < 0.05) only for the IVIgG 0.8 g/kg group, and responses to the two IgG groups were similar. These differences in response rates were reflected in the percentages of children with platelet counts of 20 x 10(9)/L or lower at 72 hours following the start of treatment: 3% (IVIgG 0.8 g/kg x 1), 6% (IVIgG 1 g/kg x 2), 18% (anti-D), and 21% (oral prednisone 4 mg/kg/day). Treatment-associated toxicities included a fall in haemoglobin with anti-D (to less than 100 g/L in 24% of cases); weight gain with oral prednisone; and fever, nausea, vomiting, and headache with IVIgG. On the basis of these results, intravenous anti-D cannot be recommended as initial therapy for children with acute ITP and platelet counts of 20 x 10(9)/L or lower. A single dose of 0.8 g/kg IVIgG offers the fastest recovery for the least treatment; additional IgG or oral prednisone can be reserved for the one-third of children who continue to have platelet counts of 20 x 10(9)/L or less at 48-72 hours after the start of treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7915773     DOI: 10.1016/s0140-6736(94)92205-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  39 in total

Review 1.  [Chronic idiopathic thrombocytopenic purpura. Current therapy concept and introduction to pathophysiologic, clinical and diagnostic aspects].

Authors:  A Böcher; F G Hagmann; H Kreiter
Journal:  Med Klin (Munich)       Date:  1998-12-15

2.  Recommendations for the use of albumin and immunoglobulins.

Authors:  Giancarlo Maria Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossettias
Journal:  Blood Transfus       Date:  2009-07       Impact factor: 3.443

3.  9 Human Immunoglobulins.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

Review 4.  Evidence-based management of immune thrombocytopenia: ASH guideline update.

Authors:  Cindy E Neunert; Nichola Cooper
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

5.  Management of immune thrombocytopenic purpura: an update.

Authors:  Rajasekharan Warrier; Aman Chauhan
Journal:  Ochsner J       Date:  2012

Review 6.  Management of idiopathic thrombocytopenic purpura.

Authors:  V P Choudhry; R Kashyap; H P Pati
Journal:  Indian J Pediatr       Date:  1998 May-Jun       Impact factor: 1.967

Review 7.  Childhood immune thrombocytopenia: Clinical presentation and management.

Authors:  Mohamed El Faki Osman
Journal:  Sudan J Paediatr       Date:  2012

8.  IVMP+IVIG raises platelet counts faster than IVIG alone: results of a randomized, blinded trial in childhood ITP.

Authors:  Manuel Carcao; Mariana Silva; Michele David; Robert J Klaassen; MacGregor Steele; Victoria Price; Cindy Wakefield; Lussia Kim; Derek Stephens; Victor S Blanchette
Journal:  Blood Adv       Date:  2020-04-14

9.  Chronic immune thrombocytopenia in a child responding only to thrombopoietin receptor agonist.

Authors:  Mohamed E Osman
Journal:  Sudan J Paediatr       Date:  2012

10.  Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia.

Authors:  Eric Cheung; Howard A Liebman
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.